Automate theme → scenario → plan
In the app, we make it easy to go from investment themes to Scenario Lab to a full thesis plan — without the busywork.
Eli Lilly's Growth Amid Competitive Landscape
LLY|September 15, 2026
Merkapital proprietary research generated from the same Thesis Plan engine (news narrative → scenario overlay → risk framework → listed-options context). For information only — not a recommendation or personalized advice.
Executive Summary
- •Thesis: Eli Lilly's recent performance and analyst upgrades highlight its strong position in the weight-loss drug market, but competition from peers like Merck poses challenges.
- •Reference spot: $1,191.74 · Scenario-implied fair value: — · Upside anchor: $1,315.04 (~+10.3% vs spot)
- •Risk framework: Volatility-adjusted stop at $1,131.74 (~5.0% below spot); risk/reward 2.05 : 1 vs modeled upside anchor.
- •Derivatives: Listed options snapshot unavailable (API: Thank you for using Alpha Vantage! Please consider spreading out your free API r).
Overview metrics
Quantitative snapshot from the Merkapital dashboard (same fields as Stocks → Overview Metrics), frozen at Thesis Plan save time.
Merkapital proprietary research (public sample)
Key developments & media context
Catalyst / news flow (seed narrative)
The following item was flagged in Market Intelligence and used as the primary media input for this note. It frames the narrative that the Thesis Plan engine then maps into scenarios, risk/reward, and options structure — it is not a stand-alone fundamental view.
Feed sentiment is neutral or unscored; the thesis map below therefore relies more heavily on headline and summary content than on automated tone labels.
Primary headline
Smith Chas P & Associates PA Cpas Has $46.21 Million Stake in Merck & Co., Inc. $MRK
Feed tone label: Neutral / not scored.
LLY · LLY · LLY · LLY · LLY
MarketBeat.
https://www.marketbeat.com/instant-alerts/filing-smith-chas-p-associates-pa-cpas-has-4621-million-stake-in-merck-co-inc-mrk-2026-09-11/
Merkapital proprietary research (public sample)
Revenue scenario
The following reflects consolidated revenue and segment mix assumptions recorded at the time this report was generated, benchmarked to the mapped segment disclosure and SEC-sourced consolidated revenue where applicable. Competitive positioning and filing references are provided for context only. These amounts represent hypothetical scenario inputs prepared in the research workflow and are not forecasts, targets, or projections of actual results.
Scenario basis: Segment mix and map baseline aligned to FY 2025 (period end 2025-12-31).
| Segment | Map % | Thesis % |
|---|---|---|
| Diabetes Care | 45.0% | 45.0% |
| Oncology | 25.0% | 25.0% |
| Neuroscience | 15.0% | 15.0% |
| Other Pharmaceuticals | 10.0% | 10.0% |
| Animal Health | 5.0% | 5.0% |
leader
$65.18B
FY 2025 (period end 2025-12-31)
Diabetes Care · Oncology · Neuroscience · Other Pharmaceuticals · Animal Health
Merkapital proprietary research (public sample)
Scenario Lab
Earnings and multiple assumptions from the Thesis Plan wizard (step 3), prior to the execution plan below.
- Last close
- $1,191.74
- Consensus EPS (next FY, baseline)
- —
- Scenario EPS
- —
- Forward P/E (baseline)
- —
- Scenario forward P/E
- —
- Street-implied (baseline)
- $1,315.04
- Scenario implied fair value
- $1,315.04
- Analyst target
- $1,315.04
- Scenario vs spot
- +10.3%
Frozen at Thesis Plan save; does not update with live quotes.
Merkapital proprietary research (public sample)
Valuation & Scenario Overlay
| Metric | Value |
|---|---|
| Last / model spot | $1,191.74 |
| Consensus analyst target (where available) | $1,315.04 |
| Scenario Lab implied price | — |
| Thesis upside anchor (options / R:R) | $1,315.04 |
| ATR-style volatility proxy (14d scale) | $40.00 |
| Annualized vol (model) | 33.3% |
| Risk per share (spot − stop) | $60.00 |
| Reward per share (anchor − spot) | $123.30 |
Merkapital proprietary research (public sample)
Risk Management & Invalidation
Volatility-adjusted stop: consider closing or reducing if price ≤ $1131.74 (entry − 1.5× ATR proxy using model volatility). Scenario upside anchor: $1315.04. Educational workflow only — not advice.
Merkapital proprietary research (public sample)
Listed Options — Expression of View
Structures are algorithmically selected from available chains (bull call spread; ~6m and ~12m anchors). Quotes may be delayed; liquidity and execution assumptions not modeled here.
API: Thank you for using Alpha Vantage! Please consider spreading out your free API r
Merkapital proprietary research (public sample)
Investment Thesis Map
Eli Lilly's Growth Amid Competitive Landscape
Rotations & relative value
Investors may rotate from Merck to Eli Lilly as LLY demonstrates stronger growth metrics in the weight-loss sector.
Constructive angles
Eli Lilly's Foundayo captures significant market share in weight-loss drugs.
LLY
Recent reports indicate that Foundayo has secured over 30% of new US patients on oral weight-loss drugs, showcasing its competitive strength.
Mechanism: Increased market share can lead to higher revenues and improved investor sentiment.
Analyst upgrades suggest a positive outlook for LLY.
LLY
Recent upgrades from analysts indicate confidence in LLY's valuation and growth potential.
Mechanism: Upgrades can drive institutional buying, boosting the stock price.
LLY is undervalued based on GF Value metrics.
LLY
An analysis suggests LLY is 25.2% undervalued, presenting a potential buying opportunity.
Mechanism: Value recognition can attract new investors looking for growth at a discount.
Cautious / bearish angles
Increased competition from Merck may pressure LLY's market share.
MRK
Merck's presence in the weight-loss drug market could dilute LLY's customer base.
Mechanism: Heightened competition may lead to price wars, impacting margins.
Market sentiment could shift due to broader economic factors.
SPY
Economic downturns or changes in healthcare policy could negatively impact pharmaceutical stocks.
Mechanism: Negative sentiment can lead to sell-offs in the sector, affecting LLY's stock price.
Second-order effects
- Increased competition may lead to innovation in drug development.
- A shift in consumer preferences towards effective weight-loss solutions could benefit LLY.
Risks & invalidation
- Failure to maintain market share could lead to revenue declines.
- Regulatory changes impacting drug pricing could affect profitability.
Suggested news monitors
Eli Lilly weight-loss drug market share · analyst upgrades Eli Lilly · Eli Lilly valuation analysis · Merck competition in pharmaceuticals
This document is generated by Merkapital's research tooling for informational and educational purposes only. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security or derivative. Scenario outputs depend on user inputs and model assumptions; actual results may differ materially.
Options involve substantial risk and are not suitable for all investors. Past performance does not guarantee future results.
Automate theme → scenario → plan
Build investment themes, stress-test them in Scenario Lab, and turn the winner into a thesis plan — faster than spreadsheets and copy-paste.
Create your 10x idea today